EXELLAR CONSULTING PTE. LTD.

Business Description

EXELLAR CONSULTING PTE. LTD. is registered as a business entity on 27 April 2017 (7.8 years ago) structured as a Exempt Private Company Limited By Shares (Local Company) with 4 officer(s) in-charge. The business jurisdiction is overseen by the Accounting and Corporate Regulatory Authority (ACRA), a government agency from Singapore with the given Business Registration Number / Unique Entity Number (UEN) 201711597G. The business official address is located at 1 Paya Lebar Link #04-01, Paya Lebar Quarter, Singapore 408533 with main trading activity as Risk Consulting And Fraud Investigations in the primary industry of 80100: Private Security Activities using Singapore Dollars - SGD as its default trading currency. The business legal name has undergone change(s) and is previously known as USSGRP SINGAPORE PTE. LTD.. The business annual account filing date falls on 31 July and is currently operational with the status of 'Live Company'. The business paid up share capital is SGD 50,333.34, with preference share capital of SGD 0, and other share capital at SGD 0.

In the past 365 days, EXELLAR CONSULTING PTE. LTD. has received a total of Login to view reported payment review(s). 12 were rated Good and Login to view were rated Poor. The latest review was made on 2023-04-12 and it was reported "Good". The aggregated good payment amount is equivalent to USD 13,080, and aggregated poor payment amount is equivalent to USD Login to view. Its current payment rating of "A" suggest a healthy payment culture where settlement with stakeholders is always prioritised. Since the business is currently active, it also signals positive financial standing. The appointment of KPMG LLP as auditor indicates that the business is medium to large sized as it is required to meet additional regulatory requirements either due to reported revenue or assets exceeding SGD 10 million or has more than 50 employees in the previous two fiscal years.

EXELLAR CONSULTING PTE. LTD. is not yet a Prompt Payment Initiative Signatory.

Last updated on 30 April 2023